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Introduction: Lung cancer represents amajor healthcare problem. Accordingly, there is an urgent need to identify
serum biomarkers for early diagnosis of lung pathology. We have recently described that patients with manifest
COPD evidence elevated levels of heat shock proteins (HSPs). Based on these data, we speculated whether HSPs
are also increased in patients with diagnosed lung cancer.
Methods: Serum levels of HSP27, phospho-HSP27 (pHSP27) and HSP70 in patients with non-small cell lung cancer
(NSCLC) diagnosed at an early (stages I–II, n=37) or advanced (stages IIIA–IV, n=72) stage were determined by
using ELISA. Healthy smokers (n=24), healthy never-smoker volunteers (n=33) and COPD patients (n=34)
according to GOLD classiﬁcation served as control population.
Results: Serum levels of HSP27were elevated in patients with NSCLC diagnosed at an early or advanced stage when
compared with both healthy control groups (Pb0.005 and Pb0.0001 respectively). Statistically signiﬁcant differ-
ences were furthermore found between the groups of patients with early vs. advanced stage NSCLC (P=0.0021).
Serum levels of HSP70 were also signiﬁcantly elevated in patients with NSCLC diagnosed at an early or at an
advanced stage when compared with either healthy control groups (P=0.0028 and Pb0.0001 respectively). In
univariate logistic regression models including healthy subjects and patients with NSCLC, HSP70 had an area
under the curve (AUC) of 0.779 (Pb0.0001) and HSP27 showed an AUC of 0.870 (Pb0.0001).
Conclusion:Our data suggest that serum HSP27 levels might serve as a possible tool to discriminate between early
and advanced stages NSCLC.© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
The relationship between smoking, lung cancer and airﬂow obstruc-
tion is well recognized [1]. It is currently well accepted that the pres-
ence of chronic airway inﬂammation is a signiﬁcant risk factor for the
development of lung cancer [2,3]. Cross-sectional studies have
evidenced that the prevalence of chronic obstructive pulmonary disease
(COPD) is 40–70% among those diagnosed with lung cancer [4]. Petty
hypothesized in an editorial [5] that COPD and lung cancer could have
common origins based on the same inﬂammatory disease process thatgery & Christian Doppler Labo-
n,Medical University of Vienna,
43 1 40400 6777; fax: +43 1
at (H.J. Ankersmit).
-NC-ND license.include genetic predisposition and environmental risk factors. Other
authors suggested that interindividual differences between genes that
control genomic integrity and those that control tissue injury may
distinguish between lung cancer and COPD outcomes in response to
inﬂammation caused by smoking [6]. Intuitively, this hypothesis
pertains to airﬂow obstruction and emphysema, two overlapping
manifestations of COPD that are related to cigarette smoking.
COPD is characterized by a largely irreversible obstruction of the
small airways due to aberrant inﬂammatory response and airway remo-
deling [7]. Chronic bronchitis and lung emphysema are pathologic
characteristics of COPD and both conditions result from progressive in-
ﬂammatory destruction of the lung parenchyma. Recently, COPD was
accepted as a disease entity featuring immunological alterations seen
in autoimmune disease. These reports demonstrated alterations in
CD8+ and CD4+ T cells as a part of the adaptive immune system
[8–10]. We have recently demonstrated that levels of systemic CD4+
CD28null T cells, a cell population described in various rheumatologic
Table 1
Characteristics of the study subjects. P-values were determined using one-way ANOVA or chi2 test for categorical variables (*Pb0.001, **Pb0.0001). Abbreviations: FVC, forced vital
capacity; FEV1, forced expiratory volume in 1 s; AC, adenocarcinoma; SCC, squamous cell carcinoma; NSCLC-NOS, NSCLC not otherwise speciﬁed.
Healthy COPD NSCLC Total P
Non-smokers Smokers GOLD I–IV Early stage Advanced stage
n 33 24 34 37 72 200 -
M/F % 48.5/51.5 37.5/62.5 60.0/40 59.5/40.5 56.9/43.1 52.5/47.5 n.s.
Age (years) 55.8±7.8 56.3±7.0 59.9±8.4 59.9±6.2 57.8±6.9 57.9±7.2 n.s.
Smoking history %
Current/Ex 0 100 100 73.0 63.9 67.4 -
Never 100 0 0 13.5 7.0 24.1 -
No details 0 0 0 13.5 29.1 8.5 -
Lung function
FVC(L) 3.73±0.98 3.52±0.85 2.80±1.08 3.50±0.81 3.18±0.91 3.3±0.99 *
FEV1(L) 2.96±0.73 2.71±0.67 1.63±0.80 2.46±0.74 2.12±0.75 2.3±0.88 **
FEV1% 99.4±9.5 92.1±13.9 52.76±23.7 79.2±20.8 71.3±22.5 76.2±25.1 **
FEV1/VC 0.80±0.06 0.77±0.06 0.57±0.14 0.70±0.11 0.66±0.13 0.69±0.14 **
Histological classiﬁcation
AC - - - 24 52 76 n.s.
SCC - - - 11 15 26 n.s.
NSCLC NOS - - - 1 5 6 -
Others - - - 1 0 1 -
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of COPD GOLD (Global Initiative for Obstructive Lung Disease) classiﬁ-
cation [11]. Moreover, we were able to evidence that manifest COPD is
associated with increased systemic release of apoptosis-speciﬁc pro-
teins asmarkers for increased cellular turnover as compared to controls
[12]. Remarkably, increased serum levels of heat shockprotein (HSP) 27
and HSP70 evidenced a high sensitivity and speciﬁcity as diagnostic
marker for manifest COPD [13]. In a further attempt, we were able to
show that increased levels of HSP27 positively correlate with the pres-
ence of air trapping and emphysema in subjectively healthy smokers
with normal lung function [14].
Recently, CT-based screening programs have clearly shown that
emphysema and chronic airway inﬂammation are associated with the
risk of lung cancer [15].
Lung cancer was not only the most commonly diagnosed malignant
disease but also the leading cause of cancer-related deaths in men in
2008 worldwide. In women, it was the fourth most frequently diag-
nosed malignancy and the second leading cause of cancer-related
deaths, worldwide.
NSCLC therapy has included surgery and (chemo)radiotherapy;
more recently, targeted drugs have been incorporated into therapeutic
protocols. However, the overall prognosis of NSCLC patients remains
poor: the ﬁve-year survival rate has been in a plateau of 15% for three
decades [16]. Given the poor prognosis for patients who present in an
advanced stage, there has been great interest in screening for lung
cancer [17]. Investigators of the National Lung Screening Trial (NLST)
observed recently that screeningwith low-dose CT signiﬁcantly reduces
mortality from lung cancer among current or ex-smokers [18]. Never-
theless, as the authors of this study themselves acknowledge, circulat-
ing molecular markers are also needed to identify individuals who are
best suited for CT screening and/or to help conﬁrm positive CT screen-
ing results. Some lung-speciﬁc serum tumor-markers, such as CEA,
CA-125, CYFRA21-1, SCC, NSE, proGRP, chromogranine, and TPA have
been evaluated in patients with NSCLC, as well as with small cell lung
cancer. Despite extensive studies, however, few have turned out to be
useful in clinic [19,20].
Based on the obvious relationship between COPD pathogenesis and
lung cancer immunology, we hypothesized that HSP27 and HSP70
levels are increased in patients with manifest NSCLC. To test this
hypothesis, peripheral blood HSP27 and HSP70 levels of early (IA–IIB)
and advanced (IIIA–IV) stages NSCLC patients were compared to those
of age-, sex-, and smoking status-matched controls by ELISA.2. Materials and methods
2.1. Study subjects
The study protocol has been approved by the Ethics Committee of
theMedical University of Vienna, Austria (EC-No.: 091/2006 respective-
ly 449/2008). Informed and written consent was obtained from
each subject included in the study and all clinical and laboratory tests
were performed in accordance with the Declaration of Helsinki and
the guidelines for Good Clinical Practice of the Medical University of
Vienna.
109 NSCLC patients and 57 healthy controls were included in this
case–control study (Table 1). Healthy smoker volunteers without any
clinical signs of cancer (n=24), healthy volunteers without any smok-
ing history nor any clinical signs of cancer (n=33), patientswithNSCLC
diagnosed at an early stage (n=37) and at an advanced stage (n=72)
were evaluated in four study groups. To prove that levels of serum
HSP27 are also augmented in patients with NSCLC but without impair-
ment of lung function we performed a subgroup analysis by differenti-
ating those NSCLC patients with (n=41) and without (n=41) COPD
classiﬁed by GOLD. In order to relate these NSCLC study group evalua-
tions we further included a patient cohort with manifest COPD staged
according to the GOLD classiﬁcation (n=34).
Diagnosis of NSCLC was conﬁrmed through histological specimens
in all cases. The caseswere staged according to operative and pathologic
ﬁndings based on seventh edition of the TNM staging system (2009) of
the International Association for the Study of Lung Cancer (IASCL) [21].
Patients with adenocarcinoma (AC), squamous cell carcinoma (SCC),
NSCLC not otherwise speciﬁed (NSCLC-NOS) and large cell carcinoma
were included in this study. Characteristics of the study subjects are
depicted in Table 1. After informed and written consent, all study sub-
jects were asked to answer a questionnaire regarding their smoking
habits, and pulmonary function parameters (forced vital capacity
[FVC], forced expiratory volume in 1 s [FEV1], and FEV1/FVC ratio)
were obtained by spirometry. Measurements were made before and –
if criteria for airﬂow obstruction were met – 15–30min after inhaling
of 200 μg salbutamol. Blood samples were collected at the time of ﬁrst
admission to the Department of Thoracic Surgery, serum was obtained
after centrifugation and aliquots were stored at −80 °C until further
testing. Exclusion criteria were any other known malignant or
inﬂammatory diseases, autoimmune diseases and alpha1-antitrypsin
deﬁciency.
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Serum levels of HSP27 were determined using adapted enzyme-
linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis,
MN, USA). Ninety-six well microtitration plates were coated overnight
at room temperature with a capture antibody against human HSP27 at
a concentration of 1 μg/ml. Plates were then washed and blocked with
block buffer for 2 h. Following another washing step, samples and stan-
dard protein in different concentrationswere added to thewells. After a
washing step, a biotin-labeled antibody was added to each well and
incubated for 2 h. After another washing step, horseradish–peroxi-
dase-conjugate (HRP) was applied for 20 min. Wells were washed,
and color reaction was achieved using tetramethylbenzidine (TMB)
(Sigma-Aldrich Corp, St. Louis, MO, USA) and the reaction was stopped
by an acid stop solution. Color developmentwas thenmonitored using a
WallacMultilabel Counter 1420 (PerkinElmer,Waltham,MA, USA). The
optical density (OD) values obtained at 450 nm were compared to the
standard curve calculated from OD values of standards with known
concentrations of antigen. Speciﬁcity was demonstrated by the manu-
facturer by Western blot analysis of the protein bound by the capture
antibody supplied in the kit. HSP70 cross reactivity was 0.23%.
2.3. Quantiﬁcation of serum pHSP27 (S78/S82)
Serum levels of phosphor-HSP27 were determined using adapted
enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Min-
neapolis, MN, USA). Ninety-six well microtitration plates were coated
overnight at room temperature with a capture antibody against
human pHSP27 at a concentration of 2 μg/ml. Plates were then washed
and blocked with block buffer for 2 h. Following another washing step,
samples and standard protein in different concentrationswere added to
the wells. After a washing step, a biotin-labeled antibody was added to
each well and incubated for 2 h. After another washing step, horserad-
ish–peroxidase-conjugate (HRP) was applied for 20 min. Wells were
washed, and color reaction was achieved using tetramethylbenzidine
(TMB) (Sigma-Aldrich Corp, St. Louis, MO, USA) and the reaction was
stopped by an acid stop solution. Color development was then moni-
tored using a Wallac Multilabel Counter 1420 (PerkinElmer, Waltham,
MA, USA). The optical density (OD) values obtained at 450 nm were
compared to the standard curve calculated from OD values of standards
with known concentrations of antigen.
2.4. Quantiﬁcation of serum HSP70
Serum levels of HSP70 were determined using adapted ELISA kits
(R&D Systems, Minneapolis, MN, USA). Ninety-six well microtitration
plates were coated overnight with a capture antibody against human
HSP70 at a concentration of 2 μg/ml. Plates were then washed and
blocked with block buffer for 2 h. Following another washing step,
samples and standard protein in different concentrations were
added to the wells. After a washing step, a biotin-labeled antibody
was added to each well and incubated for 2 h. After another washing
step, horseradish–peroxidase-conjugate was applied for 20 min.
Wells were washed, and color reaction was achieved using TMB
(Sigma-Aldrich Corp, St. Louis,MO, USA) and the reactionwas stopped
by an acid stop solution. Color developmentwas thenmonitored using
a Wallac Multilabel Counter 1420 (PerkinElmer, Waltham, MA, USA).
The OD values obtained at 450 nm were compared to the standard
curve calculated from OD values of standards with known concentra-
tions of antigen.
2.5. Statistical methods
Statistical analysis was performed using SPSS software (SPSS Inc.,
Chicago, IL, USA) and GraphPad Prism5 (GraphPad Software, La Jolla,
CA, USA) was used for data visualization. Data are given as mean±standard deviation (SD) or median and interquartile range (IQR) if
datawere not Gaussiandistributed. To determineGaussian distribution,
Shapiro–Wilk test was used. Pair-wise comparisons between groups
were performed using Student's T test. Either one-way ANOVA or, if
data were not Gaussian distributed, Kruskal–Wallis tests were used to
determine statistical signiﬁcance betweenmore than two study groups.
Categorical variables were compared using chi2 test. Univariate logistic
regression models were calculated for HSP27, pHSP27 and HSP70.
Receiver operating characteristics (ROC) curves with area under the
curve (AUC) were plotted to demonstrate sensitivity and speciﬁcity of
the evaluated serum proteins. P-values b0.05 were considered statisti-
cally signiﬁcant.3. Results
3.1. Heat shock protein 27
Serum levels of HSP27 [mean] were 1648±777 pg/ml in healthy
non-smoker controls, 2346±1080 pg/ml in healthy smokers, 3647±
1613 pg/ml in patients with early stage NSCLC, and 5364±2679 pg/ml
in patients with advanced stage NSCLC. Statistically signiﬁcant differ-
ences were found between all four groups (healthy vs. early stage,
healthy vs. advanced stage, and early vs. advanced stage: in each case
Pb0.001) (Fig. 1A). Assessment of HSP27 levels indicated no signiﬁcant
differences between the groups of COPD-free and COPD patients either
in the early or in the advanced NSCLC patient groups (Fig. 1B). Further-
more no signiﬁcant differences could be detected between the two
main histological subtypes (AC vs. SCC, P=0.116). Detailed results
(IASCL stages I to IV) of HSP27 serum levels are given in Table 2.3.2. Phospho heat shock protein 27 (S78/S82)
Serum levels of pHSP27 [median] were 315 (Q1=172, Q3=527)
pg/ml in patients with early stage NSCLC and 447 (Q1=229,
Q3=1733) pg/ml in patients with advanced disease. Statistically signiﬁ-
cant differences were found between the two groups (early vs. advanced
stage: P=0.015).3.3. Heat shock protein 70
Mean serum levels of HSP70 [mean] were 305±212 pg/ml in healthy
non-smokers, 321±316 pg/ml in healthy smoker individuals, 603±
386 pg/ml in patients with early stage NSCLC, and 793±545 pg/ml in pa-
tients with advanced disease. Statistically signiﬁcant differences were
found between healthy non-smoker controls and patients with NSCLC
diagnosed at an early or an advanced stage (P=0.0028 and Pb0.0001
respectively), between healthy smoker controls and patients diagnosed
at an early or an advanced stage (P=0.006 and Pb0.0001 respectively),
but not between the twoNSCLC groups (Fig. 1C). HSP70 levels of patients
with orwithout COPDdid not differ fromeach other signiﬁcantly in either
NSCLC groups, nor between the two main histological subtypes (AC vs.
SCC, P=0.852). Detailed results (IASCL stages I to IV) of HSP70 serum
levels are depicted in Table 2.3.4. Regression models
In univariate logistic regressionmodels including healthy volunteers
and patients with NSCLC, HSP70 had an area under the curve (AUC)
in the receiver operating characteristic (ROC) curve of 0.779
(0.707–0.851 95% conﬁdence interval; Pb0.0001), pHSP27 an AUC of
0.682 (0.580–0.783 95% conﬁdence interval; P=0.002); and HSP27
showed an AUC of 0.870 (0.817–0.923 95% conﬁdence interval;
Pb0.0001) (Fig. 2).
Fig. 1. Box plots showing mean (inner lines), inter-quartile ranges (boxes), minimum/
maximum levels (whiskers) and outside values (dots) of HSP27, pHSP27 and HSP70 serum
levels. A. Serum HSP27 levels are signiﬁcantly elevated in patients with NSCLC diagnosed
at an early (IA–IIB) or at an advanced stage (IIIA–IV) when compared with either healthy
control groups (**Pb0.01, ***Pb0.001). Between early and advanced stage NSCLC patients,
the difference is also statistically signiﬁcant (***Pb0.001). N-S, healthy never-smokers; S,
healthy smokers. B. Serum levels of HSP27 do not show any statistically signiﬁcant differ-
ences between patients with and without COPD within the two NSCLC groups. C. Serum
levels of HSP70 are elevated in patients with NSCLC diagnosed at an early (IA–IIB) or at an
advanced stage (IIIA–IV) when compared with either healthy control groups, (**Pb0.01,
***Pb0.001). However, there is no statistically signiﬁcant difference between the two
NSCLC patient groups.
Table 2
Detailed results of HSP27 and HSP70 serum levels in NSCLC patients (IASCL stages I to
IV respectively with and without COPD), COPD patients (GOLD stages I to IV) and in
healthy controls.
HSP27 HSP70
n Median IQR Median IQR
Healthy non-smokers 33 1482 1136–2071 285 166–345
Healthy smokers 24 2242 1787–3009 244 82–456
COPD GOLD I 5 3106 2740–4135 367 271–697
COPD GOLD II 15 3027 1741–3565 511 244–589
COPD GOLD III 5 4498 2568–4896 267 210–1464
COPD GOLD IV 9 4059 3002–4746 277 138–468
NSCLC I-IIb, without COPD 15 3876 2027–5665 557 353–943
NSCLC I-IIb, with COPD 14 3381 2670–4423 556 217–841
NSCLC IIIa-IV, without COPD 26 6073 2833–8428 672 429–1274
NSCLC IIIa-IV, with COPD 27 4985 3521–8112 740 284–1124
NSCLC stage Ia 10 3452 1823–4347 643 129–847
NSCLC stage Ib 15 3198 2469–4206 517 246–806
NSCLC stage IIa 3 2689 2258–4074 1014 58–1748
NSCLC stage IIb 9 4377 3105–5626 616 344–791
NSCLC stage IIIa 16 4023 3025–7355 452 282–1147
NSCLC stage IIIb 6 4339 3371–8620 825 318–1796
NSCLC stage IV 50 5558 2854–8125 719 432 – 1105
Fig. 2. ROC curve indicating sensitivity and speciﬁcity of HSP27 (AUC=0.870), pHSP27
(AUC=0.682) and HSP70 (AUC=0.779) in the diagnosis of NSCLC.
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In the present study, we found that serum HSP27 and HSP70 levels
were signiﬁcantly increased in a population of NSCLC patients as com-
pared to our sample of community based smoker and non-smoker con-
trols. In addition, serum levels of HSP27were signiﬁcantly indicative for
presence of early vs. advanced NSCLC. Furthermore impaired lung func-
tion parameters were signiﬁcantly correlated with early and advanced
stage NSCLC. This ﬁnding corroborates recently published studies that
tied CT veriﬁed lung pathologywith impaired lung function parameters
[4]. We believe that this study is the ﬁrst case–control study that provesthat HSP27 is a potential discriminator of early and advanced NSCLC
patients.
Heat shock proteins (HSPs) belong to a highly conserved protein
family and normally act as intracellular molecular chaperones which
maintain protein homeostasis. When cells are exposed to stressful
conditions, HSP synthesis gets massively triggered in order to fold
heat-denatured proteins and block caspase-dependent apoptosis, per-
mitting repair and thwarting death [22]. However, HSPs can also be
released into the circulation, where they are able to interact with the
immune cells in a number of contexts. HSPs can act as proinﬂammatory
mediators and lead to cytokine transcription and release. Through their
ability to bind antigenic peptides during antigen procession, they can
further act as stimulants of the adaptive immune response. Thus,
anti-inﬂammatory and immunosuppressive patterns of HSPs are also
described, depending on the biological microenvironment [23]. Espe-
cially HSP70, either as serum protein or cellular component, has been
studied extensively in various inﬂammatory diseases [13,24].
There is growing evidence in literature that the expression of HSPs is
increased in various human cancers. For example, HSP27 was found to
be strongly expressed in breast cancer [25], hepatomas and well differ-
entiated hepatocellular carcinomas, brain tumors [26], and prostatic
carcinoma [27]. However, a growing list of contradictory data is emerg-
ing regarding expression patterns of HSPs in lung cancer tissues and
serum/plasma samples of lung cancer patients. Michils and coworkers
[28] evaluated the quantitative expression of low molecular weight
(ubiquitin and HSP27) and high molecular weight (HSP60 and HSP70)
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and HSP70, but not HSP27 expression, was increased in cell lysates of
NSCLC tissue. In line with this conclusion is a publication authored by
Huang et al. [29]. They have studied 60 NSCLC cancer patients and were
able to demonstrate that clinicopathological features of NSCLC correlated
with tissue expressionofHSP70, but notwith the expressionofHSP27. No
statistical signiﬁcancewas observed in histological types and genderwith
respect to both HSP70 and HSP27 expression.
In contrast, Malusecka et al. [30] reported that cytoplasmic immu-
nostaining for HSP27 was positive in a high amount (70%) of samples
obtained frompatients withNSCLC. They further found a positive corre-
lation between expression levels of HSP27 and HSP70, and a correlation
between Ki-67 proliferation index and nuclear HSP70 staining. Another
publication from these authors describes a signiﬁcant survival advan-
tage in patients overexpressing HSP27 in NSCLC tissue. Furthermore, a
signiﬁcantly decreased survival was observed in those patients that
were HSP70 tissue negative [31]. Several years before, Volm and co-
workers [32] described a wide range of HSP70 levels in human NSCLCs
processed for immunostaining, possibly reﬂecting different biological
stressors. Moreover, they found a strong correlation between the num-
ber of daily smoked cigarettes and HSP70 expression in NSCLC tissue.
75% of tumors from smoker patients showed high HSP70 expression,
whereas only 57% of non-smokers presented with high HSP70 expres-
sion in the tumor samples [33]. The ﬁrst attempt to investigate the rela-
tionship between serum HSP70 levels and lung cancer was by Susuki K
et al. [34]. They detected a signiﬁcant association between elevated
serum HSP70 levels and increased lung cancer risk among Japanese
males. However, no association between lung cancer risk and HSP70
levels in female subjects could be found. A recent study investigated
the expression of HSP27 and HSP70 in coal-mine workers [35]. This
group investigated the association between plasma levels of HSP27/70
in coal-mine dust exposed miners with or without lung cancer and in
healthy controls. Interestingly, those miners exposed to coal dust with-
out cancer evidenced a signiﬁcant increment of plasma HSP27 as com-
pared to control groups.
Concluding our results, we were able to show signiﬁcantly elevated
serumHSP27 and serumHSP70 levels inNSCLCpatients comparedwith
healthy age-, sex-, and smoking status-matched controls. Furthermore,
we show that COPD patients also evidence increased HSP levels. How-
ever, we have also proven that NSCLC patients with normal lung func-
tion demonstrate increased HSP levels, indicating that both COPD and
NSCLC are related to heightened serum levels of HSP27. If we interpret
our data correctly, we feel justiﬁed to claim that COPD and NSCLC evi-
dence similar immunological features as hypothesized previously
[5,6]. Of utmost interest to us was the ﬁnding that in our highly speci-
ﬁed group analysis HSP27 was highly appropriate to differentiate be-
tween early and advanced stage NSCLC: HSP27 serum levels showed a
stage-dependent increase with 2- and 3-fold higher levels in early
(IA–IIB) vs. advanced stage (IIIA–IV) NSCLC patients. These data indi-
cate that augmented spillage of this stress protein into the systemic
circulation occurs during disease progression, presumably caused by a
continuous activation of the immune system. Further, HSP27 showed
an excellent sensitivity and speciﬁcity in a regression model to distin-
guish between healthy subjects and NSCLC patients. With an overall
area under the curve of 0.870, HSP27 is prone to serve as a possible
diagnostic marker for NSCLC progression.
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